The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.

Incyte (INCY) has reported 1Q20 EPS that included a 22% year-over-year rise in blood cancer drug Jakafi to $460 million, above consensus of $447 million.Meanwhile Q1 Non-GAAP EPS of -$2.86 missed Street expectations by $2.50 while GAAP EPS of -$3.33 also fell short by $2.08. However, excluding inclusion of $805 mln expense related to tafasitamab partnership, the P&L was in line. Revenue of $568.51M beat Street forecasts by $15.27M and represented 14.2% year-over-year growth.Following the results, JPMorgan analyst Cory Kasimov downgraded Incyte from buy to hold. However, he ramped up his price target to $99- in-line with the stock’s current share price of $98.82- from $89 previously.“We see long-term value in the company primarily driven by the Jak inhibitor, Jakafi, as well as an increasingly broad new product pipeline with late stage shots on goal (notably tafasitamab and topical ruxolitinib)” says Kasimov.“However, we reassessed our model and pulled on a number of upside levers and have a hard time justifying substantial upside at the current valuation—the basis of our N rating” he explains. INCY stock is currently trading up 33% on a three-month basis- boosted by news of Jakafi’s testing for Covid-19 related CRS, though according to the Street this would be an unlikely long-term growth driver.Indeed, Morgan Stanley’s Vikram Purohit also recently downgraded Incyte from buy to hold citing the stock’s elevated valuation, while boosting his price target from $90 to $94.The analyst comments “Following a ~35% increase in INCY over recent weeks, we believe current levels imply appropriate value for the base business and the late-stage pipeline, and we move to Equalweight.”Overall Incyte shows a cautiously optimistic Moderate Buy consensus from the Street, with analysts split between hold and buy ratings. But thanks to the stock’s rally, the $96 average analyst price target indicates 3% downside potential from current levels. (See Incyte stock analysis on TipRanks)Related News: AbbVie Scores US Antitrust Approval for $63B Allergan Deal Akebia Spikes 38% On Pivotal Trial Readout; And Further Upside Lies Ahead Gilead in Talks to Ramp Up Global Supply of Remdesivir Production More recent articles from Smarter Analyst: * Royal Caribbean Cruises Seeks $3.3 Billion Debt Sale, Moody’s Cuts Rating to Ba2 Junk Status * Tower Semiconductor Reports Q1 Earnings Beat; Top Analyst Says Buy On Weakness * Intelsat Sinks 18% On Bankruptcy Filing * Is Roku Stock a Buy Right Now? This Is What You Need to Know

Incyte revenue topped first-quarter estimates Tuesday, but Incyte stock toppled on a surprise loss and delayed clinical study amid the coronavirus pandemic. Shares are in a buy zone.

Q1 2020 Incyte Corp Earnings Call

Stock soars on promising early trial data for key drugs Continue reading...

The biotech sector remains in focus with pipeline updates on coronavirus treatments.

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

Companies in the news are: LITE, ITW, INCY, PTLA

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for 2020 guidance, the commercialization of our products, and our development plans and expectations for the compounds in our pipeline, as well as the development plans of our collaboration partners. With regards to clinical development, as of today, while our late-stage programs remain broadly on track, we anticipate that short-term effects may continue to emerge across different aspects of our global clinical trial programs, including new patient recruitment.

Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14

Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference (held virtually) on Tuesday, June 9, 2020 at 8:00 a.m. ET.

MUNICH, GERMANY / ACCESSWIRE / May 20, 2020 / MorphoSys AG (MOR.F) Prime Standard Segment; MDAX & TecDAX; (MOR) and Incyte (INCY) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), including DLBCL arising from low grade lymphoma, who are not candidates for autologous stem cell transplantation (ASCT).

Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR)Q1 2020 Earnings CallMay 9, 2020, 8:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, welcome to MorphoSys First Quarter 2020 Results Conference Call.

Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings

The quarterly results for Incyte Corporation (NASDAQ:INCY) were released last week, making it a good time to revisit...

Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.

Incyte (INCY) delivered earnings and revenue surprises of -3675.00% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?